TP-252 for treatment of
Familial Adenomatous Polyposis (FAP)
FAP is a rare genetic disease that causes proliferation of colon polyps in teenagers. This disease is usually treated with prophylactic colectomy, typically before age 20, to reduce the risk of colorectal cancer. There are currently no drugs approved for the treatment of FAP. While surgery is necessary for long-term survival, it causes significant co-morbidities and psycho-social issues affecting the health and quality of life of adolescent FAP patients.
EPA-FFA, the active ingredient in TP-252, has been shown clinically to control increases in colorectal polyp burden in FAP patients. TP-252 is designed to provide continuous management of polyp burden in conjunction with endoscopic surveillance. Improved management of disease progression may enable young FAP patients to delay surgery until they are better situated in life to handle the traumatic physical effects and emotional burden of colectomy.